Cello Buys Biotech Strategy Firm Defined Health

Healthcare and consumer marketing business Cello Group has acquired US-based biotech asset development strategy consultancy Defined Health. Terms of the deal have not been disclosed.

Founded in 1983, Defined Health focuses on drug development, business development and commercial strategy for clients involved in the fields of oncology, orphan and rare diseases, cardiometabolics, neuroscience, and other therapeutic categories. Its broad range of services includes defining target patient populations and product profiles; providing analysis of priority targets; and using its industry network to identify potential partners.

The firm will keep its name, under the Cello umbrella. Ed Saltzman, President and founder of Defined Health says the new parent's core capabilities will increase the value his team can offer clients through the full span of the process from early development to commercial launch.

Julia Ralston, CEO, Cello Health US, adds: 'We are excited to have Defined Health join our Cello Health family with the complementary fit to our consulting, insight and communication capabilities, and our focus on early drug development'.

Web sites: www.cellohealth.com and www.definedhealth.com .